526 related articles for article (PubMed ID: 29606415)
1. Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndromes and hypercholesterolemia not adequately controlled with statins: ODYSSEY J-IVUS rationale and design.
Ako J; Hibi K; Kozuma K; Miyauchi K; Morino Y; Shinke T; Tsujita K; Uno K; Kawabata Y; Hiro T
J Cardiol; 2018 Jun; 71(6):583-589. PubMed ID: 29606415
[TBL] [Abstract][Full Text] [Related]
2. Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndrome - The ODYSSEY J-IVUS Trial.
Ako J; Hibi K; Tsujita K; Hiro T; Morino Y; Kozuma K; Shinke T; Otake H; Uno K; Louie MJ; Takagi Y; Miyauchi K
Circ J; 2019 Sep; 83(10):2025-2033. PubMed ID: 31434809
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.
Teramoto T; Kondo A; Kiyosue A; Harada-Shiba M; Ishigaki Y; Tobita K; Kawabata Y; Ozaki A; Baccara-Dinet MT; Sata M
Lipids Health Dis; 2017 Jun; 16(1):121. PubMed ID: 28623954
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of alirocumab for reducing plaque vulnerability: Study protocol for ALTAIR, a randomized controlled trial in Japanese patients with coronary artery disease receiving rosuvastatin.
Otake H; Sugizaki Y; Toba T; Nagano Y; Tsukiyama Y; Yanaka KI; Yamamoto H; Nagasawa A; Onishi H; Takeshige R; Nakano S; Matsuoka Y; Tanimura K; Kawamori H; Shinke T; Hirata KI
J Cardiol; 2019 Mar; 73(3):228-232. PubMed ID: 30579806
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of alirocumab 150mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON.
Teramoto T; Kiyosue A; Ishigaki Y; Harada-Shiba M; Kawabata Y; Ozaki A; Baccara-Dinet MT; Sata M
J Cardiol; 2019 Mar; 73(3):218-227. PubMed ID: 30509509
[TBL] [Abstract][Full Text] [Related]
6. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Schwartz GG; Bessac L; Berdan LG; Bhatt DL; Bittner V; Diaz R; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Mahaffey KW; Moryusef A; Pordy R; Roe MT; Rorick T; Sasiela WJ; Shirodaria C; Szarek M; Tamby JF; Tricoci P; White H; Zeiher A; Steg PG
Am Heart J; 2014 Nov; 168(5):682-9. PubMed ID: 25440796
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials.
Kereiakes DJ; Lepor NE; Gerber R; Veronica Lee L; Elassal J; Thompson D; Michael Gibson C
Atherosclerosis; 2018 Oct; 277():211-218. PubMed ID: 30025648
[TBL] [Abstract][Full Text] [Related]
8. Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-Rationale and design of the PACMAN-AMI trial.
Zanchin C; Koskinas KC; Ueki Y; Losdat S; Häner JD; Bär S; Otsuka T; Inderkum A; Jensen MRJ; Lonborg J; Fahrni G; Ondracek AS; Daemen J; van Geuns RJ; Iglesias JF; Matter CM; Spirk D; Juni P; Mach F; Heg D; Engstrom T; Lang I; Windecker S; Räber L
Am Heart J; 2021 Aug; 238():33-44. PubMed ID: 33951415
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials.
Colhoun HM; Robinson JG; Farnier M; Cariou B; Blom D; Kereiakes DJ; Lorenzato C; Pordy R; Chaudhari U
BMC Cardiovasc Disord; 2014 Sep; 14():121. PubMed ID: 25240705
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.
Kereiakes DJ; Robinson JG; Cannon CP; Lorenzato C; Pordy R; Chaudhari U; Colhoun HM
Am Heart J; 2015 Jun; 169(6):906-915.e13. PubMed ID: 26027630
[TBL] [Abstract][Full Text] [Related]
11. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
12. Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study.
Pérez de Isla L; Díaz-Díaz JL; Romero MJ; Muñiz-Grijalvo O; Mediavilla JD; Argüeso R; Sánchez Muñoz-Torrero JF; Rubio P; Álvarez-Baños P; Ponte P; Mañas D; Suárez Gutierrez L; Cepeda JM; Casañas M; Fuentes F; Guijarro C; Ángel Barba M; Saltijeral Cerezo A; Padró T; Mata P;
Circulation; 2023 May; 147(19):1436-1443. PubMed ID: 37009731
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies.
Robinson JG; Colhoun HM; Bays HE; Jones PH; Du Y; Hanotin C; Donahue S
Clin Cardiol; 2014 Oct; 37(10):597-604. PubMed ID: 25269777
[TBL] [Abstract][Full Text] [Related]
14. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial.
Räber L; Ueki Y; Otsuka T; Losdat S; Häner JD; Lonborg J; Fahrni G; Iglesias JF; van Geuns RJ; Ondracek AS; Radu Juul Jensen MD; Zanchin C; Stortecky S; Spirk D; Siontis GCM; Saleh L; Matter CM; Daemen J; Mach F; Heg D; Windecker S; Engstrøm T; Lang IM; Koskinas KC;
JAMA; 2022 May; 327(18):1771-1781. PubMed ID: 35368058
[TBL] [Abstract][Full Text] [Related]
15. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJ; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Scott R; Ungi I; Podolec J; Ophuis AO; Cornel JH; Borgman M; Brennan DM; Nissen SE
JAMA; 2016 Dec; 316(22):2373-2384. PubMed ID: 27846344
[TBL] [Abstract][Full Text] [Related]
16. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.
Stroes E; Guyton JR; Lepor N; Civeira F; Gaudet D; Watts GF; Baccara-Dinet MT; Lecorps G; Manvelian G; Farnier M;
J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27625344
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.
Okere AN; Serra C
Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279
[TBL] [Abstract][Full Text] [Related]
19. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.
Müller-Wieland D; Leiter LA; Cariou B; Letierce A; Colhoun HM; Del Prato S; Henry RR; Tinahones FJ; Aurand L; Maroni J; Ray KK; Bujas-Bobanovic M
Cardiovasc Diabetol; 2017 May; 16(1):70. PubMed ID: 28545518
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
McCullough PA; Ballantyne CM; Sanganalmath SK; Langslet G; Baum SJ; Shah PK; Koren A; Mandel J; Davidson MH
Am J Cardiol; 2018 Apr; 121(8):940-948. PubMed ID: 29472008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
